The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan

Value in Health Regional Issues

Volumn 3, Issue 1, 2014, Pages 50-58

  Kumada, Hiromitsu ^a   DaCosta DiBonaventura, Marco ^b   Yuan, Yong ^c   Kalsekar, Anupama ^c   Kopenhafer, Lewis ^b   Tang, Ann ^d   Victor, Timothy W ^b   L'Italien, Gilbert ^c,e   Chayama, Kazuaki ^f   Toyota, Joji ^g  

^a TORANOMON HOSPITAL   (Japan)

^b KANTAR HEALTH   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Healtheconomics Research Group   (Japan)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HIROSHIMA UNIVERSITY   (Japan)

^g Sapporo Kosei General Hospital   (Japan)

Author keywords

Adherence; Adverse events; Hepatitis C; Interferon; Quality of life; Resource use; Satisfaction; Work impairment

Indexed keywords

LIVER PROTECTIVE AGENT; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DYSGEUSIA; DYSPNEA; EMERGENCY WARD; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEPATITIS C; HOSPITALIZATION; HUMAN; INSOMNIA; JAPAN; JOB PERFORMANCE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MUSCLE WEAKNESS; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SCORING SYSTEM;

EID: 84901192258     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2014.01.002     Document Type: Article

References (37)

1. Higuchi M., Tanaka E., Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis 2002, 55:69-77.
2. Lavanchy D., McMahon B. Worldwide prevalence and prevention of hepatitis C. Hepatitis C. 2000, Academic Press, San Diego. T.J. Liang, J.H. Hoofnagle (Eds.).
3. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
4. Yoshizawa H., Tanaka J., Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 2006, 49:7-17.
5. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002, 62(Suppl. 1):8-17.
6. Chayama K., Hayes C.N., Ohishi W., et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol 2013, 48:1-12.
7. Chung H., Ueda T., Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010, 53:39-43.
8. Kanda T., Yokosuka O., Omata M. Treatment of hepatitis C virus infection in the future. Clin Transl Med 2013, 2:9.
9. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
10. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157:867-876.
11. Wesche B., Jaeckel E., Trautwein C., et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001, 48:378-383.
12. Lisker-Melman M., Di Bisceglie A.M., Usala S.J., et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992, 102:2155-2160.
13. Iwasaki Y., Ikeda H., Araki Y., et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006, 43:54-63.
14. Younossi Z., Kallman J., Kincaid J. The effects of HCV infection and management on health related quality of life. Hepatology 2007, 45:806-816.
15. Ware J.E., Bayliss M.S., Mannocchia M., et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999, 30:550-555.
16. Bianchi G., Loguercio C., Sgarbi D., et al. Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. Dig Liver Dis 2000, 32:398-405.
17. Dan A.A., Martin L.M., Crone C., et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006, 44:491-498.
18. Brook R.A., Kleinman N.L., Su J., et al. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care 2011, 17:657-664.
19. Liu G.G., DiBonaventura M.D., Yuan Y., et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012, 15(Suppl):S65-S71.
20. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
21. Bayliss M.S., Gandek B., Bungay K.M., et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998, 7:39-55.
22. User's Manual for the SF-36v2 Health Survey 2011, QualityMetric Incorporated, Lincoln, RI. 3rd ed. M.E. Maruish (Ed.).
23. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993, 4:353-365.
24. Atkinson M.J., Sinha A., Hass S.L., et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004, 2:12.
25. Morisky D.E., Ang A., Krousel-Wood M., et al. Predictive validity of a medication adherence measure for hypertension control. J Clin Hypertens 2008, 10:348-354.
26. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998, 339:1493-1499.
27. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339:1485-1492.
28. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
29. Kuwabara H. Treatment burden associated with peginterferon-based antiviral therapy for patients with chronic hepatitis C (CHC) in Japan. Presented at: the International Society of Pharmacoeconomics Conference. New Orleans, LA May 2013.
30. DiBonaventura M.D., Fukuda T., Stankus A.P. The effect of neuropathic pain on health status, work productivity loss, and healthcare resource use in Japan. Presented at: the International Society of Pharmacoeconomics Asia-Pacific Conference. Taipei, Taiwan September 2012.
31. DiBonaventura M.D., Fukuda T., Stankus A.P. The prevalence and burden of comorbid hypertension and obesity among patients with type 2 diabetes. Presented at: the International Society of Pharmacoeconomics Asia-Pacific Conference. Taipei, Taiwan September 2012.
32. Hassanein T., Cooksley G., Sulkowski M., et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004, 40:675-681.
33. McHutchison J.G., Ware J.E., Bayliss M.S., et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001, 34:140-147.
34. Perrillo R., Rothstein K.D., Rubin R., et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004, 11:157-165.
35. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(Suppl.):S237-S244.
36. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
37. Bernstein D., Kleinman L., Barker C.M., et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35:704-708.